<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="761993" id="root" date="1997-07-29" xml:lang="en">
<title>USA: IPO HIGHLIGHTS-Galileo jumps at debut.</title>
<headline>IPO HIGHLIGHTS-Galileo jumps at debut.</headline>
<dateline>NEW YORK 1997-07-29</dateline>
<text>
<p>Galileo Technology Ltd shares surged more than 58 percent on its first day of trading Tuesday from its initial public offering price of $17 a share.</p>
<p>The stock was up 9-7/8 to 26-7/8 in late trading on the Nasdaq. Galileo, which makes semiconductors for digital communication network equipment, sold three million shares.</p>
<p>In the original U.S. Securities and Exchange Commission filing, the Karmiel, Israel-based company expected to sell 250,000 fewer shares for between $10 to $12 each.  The underwriters, led by Alex Brown &amp; Sons, have an option to buy 450,000 more shares to cover any over-allotments, if any.  </p>
<p>Other companies that made their IPO debuts today:</p>
<p>-- Bioreliance Corp shares jumped to 18 from an IPO price of $15 a share, above initial expectations. It first set a pricing range for the 2.4 million shares offered at $12-$14 but raised the range to $14 to $15 due to heavy demand. It sold 2.1 million of the total shares while selling shareholders offered the remainder. Morgan Stanley Dean Witter was the lead underwriter of the offering.</p>
<p>Bioreliance, based in Rockville, Maryland, provides nonclinical testing and contract manufacturing services to biotechnology companies. It was founded as Microbiological Associates Inc in 1947.  </p>
<p>The company said it would used for capital expenditures, expansion of viral manufacturing capabilities, working capital and other general corporate purposes, including potential acquisitions, the company said.</p>
<p>-- Shares of Net.B@nk Inc slid on their first day of trading despite a generally favorable climate for IPOs.</p>
<p>The Atlanta internet bank sold 3.5 million shares, up from an original plan to offer three million, for $12 each, the top of its estimated price range of $10 to $12. Morgan Keegan &amp; Co Inc was the lead underwriter of the offering.</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-29"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I34531">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-29"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C15">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-29"/>
  </code>
  <code code="C152">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-29"/>
  </code>
  <code code="C17">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-29"/>
  </code>
  <code code="C171">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-29"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-07-29"/>
  </code>
</codes>
<dc element="dc.date.created" value="1997-07-29"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-07-29"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="NEW YORK"/>
<dc element="dc.creator.location.country.name" value="USA"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
